Author: Saeed, Abdullah F. U. H.; Wang, Rongzhi; Ling, Sumei; Wang, Shihua
Title: Antibody Engineering for Pursuing a Healthier Future Document date: 2017_3_28
ID: 0fegsm1v_108
Snippet: Similarly, new opportunities have been created by the development of antibody-drug conjugates (ADCs) to treat the infectious diseases or target cancer cells. ADCs are being developed by progressing in antibody generation, selection of exceedingly cytotoxic molecules, and construction of stable linkers that can be investigated in clinical trials (Vincent and Zurini, 2012) . Cytotoxic therapeutic mAbs often help target cell-killing by eliciting imm.....
Document: Similarly, new opportunities have been created by the development of antibody-drug conjugates (ADCs) to treat the infectious diseases or target cancer cells. ADCs are being developed by progressing in antibody generation, selection of exceedingly cytotoxic molecules, and construction of stable linkers that can be investigated in clinical trials (Vincent and Zurini, 2012) . Cytotoxic therapeutic mAbs often help target cell-killing by eliciting immune effector functions. These include antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) mediated by innate immune effector cells, and complementdependent cytotoxicity (CDC) mediated by humoral components (Figure 6) . in vitro studies, Fc engineering methods have been specifically designed to modulate ADCC, ADCP, and CDC envisioned for therapeutic mediation (Kinder et al., 2015) .
Search related documents:
Co phrase search for related documents- antibody dependent cellular phagocytosis and clinical trial: 1, 2
- antibody dependent cellular phagocytosis and effector cell: 1, 2, 3
- antibody drug and cancer cell: 1, 2, 3, 4, 5, 6, 7, 8
- antibody drug and cancer cell target: 1
- antibody drug and cell killing: 1, 2, 3
- antibody drug and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8
- antibody drug and effector function: 1
- antibody drug and infectious disease: 1, 2
- antibody drug conjugate and cancer cell: 1, 2
- antibody drug conjugate and cell killing: 1
- antibody drug conjugate and clinical trial: 1, 2, 3
- antibody generation and cancer cell: 1
- antibody generation and cell killing: 1
- antibody generation and cellular phagocytosis: 1, 2
- antibody generation and effector cell: 1
- antibody generation and effector function: 1
- antibody generation and engineering method: 1
- antibody generation and infectious disease: 1, 2
- antibody generation and stable linker: 1
Co phrase search for related documents, hyperlinks ordered by date